Pharma Data Associates


Pharma Data Associates is a company of statisticians, SAS programmers, and clinical data managers with extensive experience supporting clinical development in biopharmaceutical companies and government agencies. Their mission is to provide high-quality, flexible, and results-oriented biometrics support as an extension of their clients' teams, ensuring regulatory compliance and efficient data management. They offer a wide range of biostatistics, data management, and regulatory submission services, with a focus on FDA eSubmission standards and CDISC compliance.

Industries

biopharma
data-management-7932
pharmaceutical

Nr. of Employees

small (1-50)

Pharma Data Associates


Services

Comprehensive biostatistics services including trial design, power/sample-size calculations, SAP development, interim analyses, mock TLFs, and CSR review.

Mapping raw clinical data to SDTM, creation of ADaM datasets and Define.xml, assembly of eSubmission folder structures and XPT datasets compliant with FDA requirements.

eCRF and CRF design, edit-check specification, UAT, data management planning, query resolution, external data reconciliation, SAE reconciliation, metric reporting and database lock.

SAS programming for TLFs, analysis dataset generation, and development of graphical tools such as patient profile plots and forest plots to aid safety and efficacy review.

Consulting on adaptive and group-sequential designs, Bayesian stopping rules, conditional power calculations, and sample-size re-estimation to optimize trial duration and cost.

Expertise Areas

  • Clinical trial biostatistics
  • Statistical programming (SAS)
  • Clinical data management and EDC/CDASH
  • CDISC standards and FDA eSubmission preparation
  • Show More (4)

Key Technologies

  • SAS programming
  • CDISC SDTM
  • CDISC ADaM
  • Define.xml
  • Show More (6)

News & Updates

Rescue Mission for an NDA Submission

NDA re-prepared with amended phase 3 CSRs, new ISS, and new statistics data package compliant to the FDA eSubmission requirement, completed in 2.5 months.

Cost Savings as a Result of Sample Size Reduction

Early termination of trials using Bayesian methods, resulting in 50% cost saving, and sample size re-estimation reducing trial length by 30%.

Consideration in Study Design

Mid-course modification of a group sequential trial and a non-inferiority study design for a cardiovascular drug with MACE endpoint.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.